TMO

Several major companies exceeded third-quarter 2026 earnings expectations, driving positive stock movements. Capital One Financial surpassed estimates with $6.69 EPS, Bank OZK beat forecasts with $1.50 EPS, Thermo Fisher Scientific exceeded expectations with $6.68 EPS, and Danaher Corp. outperformed with $2.11 EPS.

Thermo Fisher Scientific raised its full-year 2026 organic revenue growth guidance to 4% following strong Q3 results with $12.14 billion in revenue and 6% organic growth. The company is leveraging AI integration to reduce manual laboratory setup time by 90%, accelerating workflows and boosting recurring sales. Strategic acquisitions like Clario are expanding clinical development capabilities and creating revenue synergies, positioning the company for durable margin expansion amid strengthening biopharmaceutical research activity.

Thermo Fisher Scientific (TMO) reported quarterly earnings of $6.68 per share, beating consensus estimates of $6.4 and surpassing revenue expectations at $12.14 billion. The company has outperformed the market by 17.3% year-to-date and maintains a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. Integer Holdings (ITGR), another medical device company, is expected to report declining earnings and revenues in its upcoming quarter.

Thermo Fisher Scientific (TMO) is highlighted as a stock well-positioned to maintain its earnings-beat streak, with a positive Earnings ESP of +0.07% and a Zacks Rank #2 (Buy) rating. The company has demonstrated consistent earnings surprises, averaging 5.11% over the past two quarters, with its next earnings report expected on October 21, 2026.

The global clinical trial supplies market is projected to grow from $5.7 billion in 2025 to $10.7 billion by 2033, expanding at a CAGR of 8.4%. Growth is driven by rising R&D investments, increasing chronic disease prevalence, and demand for specialized logistics for biologics, personalized medicine, and decentralized trials. Key players include Thermo Fisher Scientific, Catalent, Almac Group, and UPS Healthcare.

Thermo Fisher Scientific is set to report Q3 2026 results on October 21, with consensus estimates projecting 7.1% revenue growth to $11.91B and 10.5% EPS growth to $6.40. The company's Life Sciences Solutions and Laboratory Products segments are expected to drive growth at 10.1% and 9.8% respectively, supported by recent product innovations. However, Specialty Diagnostics revenues are projected to decline 3% following the sale of its microbiology business to Astorg for $1.075 billion.

Thermo Fisher Scientific (TMO) has been upgraded to Zacks Rank #2 (Buy) due to upward trends in earnings estimates. The upgrade reflects improving business fundamentals, with analysts raising consensus estimates by 1.1% over the past three months. The stock is positioned in the top 20% of Zacks-covered stocks based on earnings estimate revisions, suggesting potential near-term price appreciation.

Thermo Fisher Scientific (TMO) is strengthening growth through innovation, AI investments, and strategic acquisitions expected to contribute $1.6 billion in revenues and 32 cents to adjusted EPS in 2026. The company expects organic revenue growth at 3%-4% for 2026 supported by broad-based end-market improvements. However, risks from macroeconomic uncertainty, inflation, geopolitical disruption, and unfavorable currency movements could weigh on results and margins.

Quantum BioPharma has entered into a Study Start-Up Agreement with Thermo Fisher Scientific's PPD Clinical Research Business to implement its Phase 2 clinical trial of Lucid-MS, an investigational neuroprotective therapy targeting demyelination in progressive multiple sclerosis. The agreement marks a significant milestone following FDA clearance and represents the initiation of formal study start-up activities.

The Medical Instruments industry is experiencing growth driven by generative AI adoption, with the AI-enabled medical devices market projected to expand at 19.9% CAGR through 2034. The industry carries a Zacks Industry Rank #86 (top 35%), though it has underperformed the S&P 500 and broader sector over the past year. Three stocks highlighted for potential outperformance are Globus Medical (Rank #1), Intuitive Surgical (Rank #2), and Thermo Fisher Scientific (Rank #2), all benefiting from AI integration, M&A activity, and strong earnings growth projections.

Forge's Fierce Life Sciences announced finalists for the 2026 Fierce Life Science and Healthcare Innovation Awards, recognizing breakthrough innovations across AI, biotechnology, digital health, and medical devices. The inaugural Fierce Vanguard Gala on November 19, 2026, in New York City will consolidate three recognition programs (Fierce 50, Fierce 15, and Innovation Awards) and announce winners live.

The U.S. economy showed mixed signals with rising inflation (3.7% headline, 2.6% core) and geopolitical tensions pressuring markets. The Nasdaq fell 4.1% while the Dow gained 0.29%, reflecting investor preference for blue-chip stocks over tech. Despite market uncertainty, Zacks' research-driven rating systems demonstrated strong performance, with Valero Energy gaining 29.7% post-upgrade, Palantir surging 40.5% over 12 weeks, and the Zacks Rank #1 portfolio outperforming the S&P 500 by 3.9 percentage points year-to-date.

The global microbiology testing market is projected to grow from USD 6.3 billion in 2025 to USD 13.7 billion by 2034, driven by increasing infectious disease prevalence, antimicrobial resistance concerns, and stringent regulatory requirements. North America leads with 42% market share, while Asia-Pacific is expected to record the fastest growth. Key drivers include technological advancements in molecular diagnostics, laboratory automation, and expanding clinical diagnostic infrastructure.

The global Decentralized Clinical Trials (DCT) market is valued at $8.8 billion in 2025 and is projected to reach $18.8 billion by 2030, growing at a 13.7% CAGR. Growth is driven by AI integration, wearable technologies, cloud-based platforms, and increased adoption of remote research capabilities across pharmaceutical, biotechnology, and contract research sectors.

The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR.

Zacks Research showcased strong performance across its various investment portfolios and rating systems during the week ended October 2, 2026. Multiple stocks received upgrades and delivered significant gains, including CRCT and PGEN surging 32% and 30.8% respectively following recommendation upgrades. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while the Focus List portfolio returned 19.86% versus 13.14% for the S&P 500 through August 31, 2026.

The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

The global oligonucleotide synthesis reagents market is valued at USD 723.3 million in 2025 and is projected to reach USD 1.75 billion by 2033, growing at a 11.9% CAGR. Growth is driven by increasing demand for nucleic acid-based therapeutics including siRNA, antisense oligonucleotides, CRISPR gene editing, and mRNA platforms across oncology, rare genetic disorders, and infectious diseases.

The global cell and gene therapy biomanufacturing market is projected to grow from $5.0 billion in 2026 to $8.7 billion by 2031, driven by an 11.7% CAGR. Growth is fueled by increasing regulatory approvals, rising demand for scalable manufacturing infrastructure, and investments in automation and modular systems. However, high production costs, regulatory complexity, and workforce shortages remain significant challenges.

The global magnetic beads market is projected to grow from USD 3.90 billion in 2026 to USD 6.18 billion by 2032, driven by automation, molecular diagnostics, genomics, and bioprocessing applications. Key growth drivers include adoption of automated magnetic separation platforms, advanced surface chemistries, AI-enabled workflow optimization, and expanding diagnostics capacity across regions. Strategic priorities for industry leaders include developing application-specific chemistries, strengthening supply-chain resilience, and leveraging AI analytics.